Fig. 7

Combination of nitric oxide donors and cisplatin induces an additive therapeutic effect in vivo. (A) Schematic representation of the combination treatment schedule of cisplatin and SNAP. (B) LL2 tumor-bearing mice were administered cisplatin (5 mg/kg), SNAP (0.004 mg/kg) or both, and tumor growth was measured. (C) The Kaplan–Meier survival curve of mice administered combination treatment with low-dose SNAP and cisplatin. (D) LL2 tumor-bearing mice were administered cisplatin (5 mg/kg), SNP (0.1 mg/kg) or both, and tumor growth was measured. (E) The Kaplan–Meier survival curve of the mice administered combination treatment with low-dose SNP and cisplatin. (F) CT26 tumor-bearing mice were treated with cisplatin (5 mg/kg), SNAP (0.004 mg/kg) or both, and tumor growth was measured. The p-values of the tumor growth curve were obtained by two-way ANOVA, *p < 0.05, **p < 0.01, ***p < 0.001. The log-rank p-values of the survival curve were obtained using the log-rank (Mantel‒Cox) test. The tumor volumes were measured every 2-4 days after tumor implantation